Research analysts at Maxim Group initiated coverage on shares of Can Fite Biopharma Ltd (NASDAQ:CANF) in a research report issued to clients and investors on Friday, Marketbeat reports. The brokerage set a “buy” rating and a $7.00 price target on the stock. Maxim Group’s target price would indicate a potential upside of 357.52% from the stock’s current price.

Separately, HC Wainwright set a $6.00 target price on shares of Can Fite Biopharma and gave the company a “buy” rating in a research note on Thursday.

Shares of Can Fite Biopharma (NASDAQ:CANF) opened at 1.53 on Friday. The stock’s 50 day moving average price is $1.77 and its 200-day moving average price is $1.85. The stock’s market cap is $23.72 million. Can Fite Biopharma has a 52-week low of $1.50 and a 52-week high of $2.82.

TRADEMARK VIOLATION NOTICE: “Can Fite Biopharma Ltd (NASDAQ:CANF) Receives New Coverage from Analysts at Maxim Group” was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://www.dailypolitical.com/2017/08/11/can-fite-biopharma-ltd-nasdaqcanf-receives-new-coverage-from-analysts-at-maxim-group.html.

Can Fite Biopharma Company Profile

Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases.

Receive News & Ratings for Can Fite Biopharma Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can Fite Biopharma Ltd and related companies with MarketBeat.com's FREE daily email newsletter.